1.Dose and Treatment Duration of Regimen.
The Korean Journal of Hepatology 2005;11(1):13-16
No abstract available.
Antiviral Agents/administration & dosage
;
Hepatitis B, Chronic/*drug therapy
;
Humans
3.Hepatitis C Viral Kinetics as a Determinant of Stopping Pegylated Interferon and Ribavirin in Genotype 1 Infection.
Gut and Liver 2014;8(4):335-336
No abstract available.
Antiviral Agents/*administration & dosage
;
Female
;
Hepatitis C, Chronic/*drug therapy
;
Humans
;
Interferon-alpha/*administration & dosage
;
Male
;
Polyethylene Glycols/*administration & dosage
;
Recombinant Proteins/administration & dosage
;
Ribavirin/*administration & dosage
4.Oromucosal Cytokine Therapy: Mechanism(s) of Action.
The Korean Journal of Hepatology 2002;8(2):125-131
Oromucosal cytokine therapy allows large amounts of cytokines to be administered with improved outcome and without dose limiting toxicity. Orally administered cytokines exert their effects by a novel two pronged mechanism of action. Firstly, specific populations of immuno-competent effector cells are activated in the oral cavity and migrate to the site of virus replication. Secondly, chemokines produced in the lymphoid tissue of the oral cavity enter the peripheral circulation and redirect activated lymphocytes to eliminate virus infected cells. Oromucosal IFN therapy constitutes an alternative and improved means of therapy for diseases such as chronic viral hepatitis which are currently treated parenterally with IFN alpha. The oral route also has obvious advantages for ease of administration and improved patient compliance. Furthermore, the availability of a well tolerated form of IFN therapy will also allow Type I IFNs to be used for the treatment of diseases such as upper respiratory tract virus infections, for which parenteral IFN therapy is currently precluded due to unacceptable toxicity.
Administration, Oral
;
Animals
;
Antineoplastic Agents/administration & dosage
;
Antiviral Agents/*administration & dosage/adverse effects/pharmacology
;
Hepatitis, Viral, Human/drug therapy
;
Human
;
Interferon-alpha/*administration & dosage/adverse effects/pharmacology
5.Preparation of acyclovir liposome and study on its stability.
Acta Pharmaceutica Sinica 2003;38(7):552-554
AIMTo prepare acyclovir liposome for improvement the entrapment efficiency and stability.
METHODSAcyclovir liposome was prepared by the reverse evaporating method. Surfactants such as sodium deoxycholate and oleic acid were added to optimize the conditions and technology of preparing acyclovir liposome. The entrapment efficiency and particle size of the acyclovir liposome were determined. The liposome stability was proved by centrifugal acceleration experiment.
RESULTSThe particle size of the acyclovir liposome was 219.8 nm with the polydispersity index of 0.158. The entrapment efficiency reached 65%. The liposome was stable.
CONCLUSIONThe results suggest that the conditions and technology are stable and practical to prepare the liposome with high entrapment efficient and stability.
Acyclovir ; administration & dosage ; Antiviral Agents ; administration & dosage ; Drug Carriers ; Drug Stability ; Liposomes ; chemistry ; Particle Size ; Technology, Pharmaceutical ; methods
7.Therapeutic effect of ribavirin aerosol on herpangina in children.
Hua-Fang WANG ; Jian-Di LI ; Xiao-Fang ZHAO
Chinese Journal of Contemporary Pediatrics 2009;11(6):494-495
Aerosols
;
Antiviral Agents
;
administration & dosage
;
Child
;
Child, Preschool
;
Female
;
Herpangina
;
drug therapy
;
Humans
;
Infant
;
Male
;
Ribavirin
;
administration & dosage
9.Long-Term Suppression of Viral Replication in Chronic Hepatitis B: Outcomes and Future Directions.
Gut and Liver 2015;9(3):265-266
No abstract available.
Antiviral Agents/*administration & dosage
;
*Disease Progression
;
Female
;
Hepatitis B, Chronic/*drug therapy/*pathology
;
Humans
;
Male